Skip to content

For Canadian Healthcare Professionals Only

Sanofi

Sarclisa (isatuximab)

English Français

Mechanism of Action

Mechanism of Action*,1

SARCLISA® is a monoclonal antibody that binds to a specific extracellular epitope of CD38 and triggers several mechanisms leading to the death of CD38-expressing tumour cells.

An image of a myeloma cell expressing CD38 on the cell surface. SARCLISA® molecules are surrounding the cell, and some have bound to CD38 receptors.

IgG Fc-Dependent Mechanisms

SARCLISA® acts through IgG Fc-dependent mechanisms, including antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis and complement-dependent cytotoxicity.

Inhibits Enzymatic Activity

SARCLISA® inhibits the enzymatic activity of CD38, which may contribute to immunoregulatory functions.

Apoptosis

SARCLISA® induces apoptosis via an Fc-independent mechanism.

*Clinical significance is unknown.

Image is an artist’s rendition and is not to scale. Adapted from SARCLISA® Product Monograph.

CD38 = cluster of differentiation 38; Fc = fragment crystallizable; IgG = immunoglobulin G.

Pharmacodynamics*,1

The pharmacodynamic activity of SARCLISA® was characterized in monotherapy.

An image of a myeloma cell expressing CD38 on the cell surface. SARCLISA® molecules are surrounding the cell, and some have bound to CD38 receptors.

Activates NK Cells

In vitro, SARCLISA® can activate NK cells in the absence of CD38-positive target tumour cells through a mechanism that is dependent on the Fc portion of SARCLISA®.

Inhibits Tregs

SARCLISA® inhibits Tregs, which express higher levels of CD38 in multiple myeloma patients compared with healthy individuals.†

*Clinical significance is unknown.

†Observed effects.

Image is an artist’s rendition and is not to scale. Adapted from SARCLISA® Product Monograph.

CD38 = cluster of differentiation 38; Fc = fragment crystallizable; NK = natural killer; Tregs = regulatory T cells.

Reference

  1. PrSARCLISA® Product Monograph. Sanofi Canada. January 12, 2024.